Summary
In this study, the vasodilating properties of captopril and zofenoprilat, two angiotensin-converting enzyme (ACE) inhibitors containing the sulfhydryl group, are investigated in the isolated rat heart. It is demonstrated that both compounds increase coronary flow in a dose-dependent manner. However, the mean pD2 of zofenoprilat appears to be significantly higher than the mean pD2 of captopril (4.55 ± 0.06 and 3.35 ± 0.02 respectively), indicating that zofenoprilat is about ten times more potent in increasing coronary flow than captopril. Possibly this difference in potency between captopril and zofenoprilat can be explained by their physicochemical properties. Since zofenoprilat is more lipophilic than captopril, its concentration in cardiac and vascular tissues at distribution equilibrium is thought to be higher than the tissue concentration of captopril, which may result in a more pronounced vasodilatory action.
The precise mechanism of coronary vasodilation induced by ACE inhibitors containing the sulfhydryl group is not yet understood. Several factors have been proposed, such as stimulation of prostacyclin production. However, in this study, concomitant administration of 10−6 mol/l acetylsalicylic acid shows no antagonism, indicating that under normoxic conditions the vasodilatory effects of captopril and zofenoprilat are independent of the production of vasodilating prostaglandins. Therefore, other factors than stimulation of prostacyclin synthesis seem to be involved, such as prevention of bradykinin breakdown and/or potentiation of endothelium derived relaxing factor (EDRF). Furthermore, despite a marked inhibition of prostacyclin production, 10−6 mol/l acetylsalicylic acid itself has no effect on coronary flow. These results suggest that prostacyclin does not play an important role in the regulation of coronary flow, at least in the normoxic isolated rat heart.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ariëns EJ, Simonis AM, Van Rossum JM (1964) One receptor systems. In: Ariëns EJ (ed) Molecular pharmacology — the mode of action of biologically active compounds, vol 1. Academic Press, New York, pp 120–269
Björnsson OG, Kobayashi K, Williams JR (1988) Modulation of coronary flow rate and cardiac contractility by the divalent cation ionophore A23187 and inhibitors of the cyclooxygenase and 5-lipoxygenase pathways: development of heterogenous patterns of myocardial ischemia. Naunyn-Schmiedeberg's Arch Pharmacol 337:191–202
Boeynaems JM (1988) Drugs influencing the vascular production of prostacyclin. Prostaglandins Leukot Essent Fatty Acids 34:197–204
Campbell DJ (1987) Tissue renin-angiotensin system: sites of angiotensin formation. J Cardiovasc Pharmacol 10 [Suppl 7]: S1-S8
Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM (1989) Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 2:294–306
Drexler H, Depenbusch W, Truog AG, Zelis R, Flaim F (1987) Acute regional vascular effects of intravenous captopril in a rat model of myocardial infarction and failure. J Pharmacol Exp Ther 241:13–19
Düsing R, Scherag R, Landsberg G, Glanzer K, Kramer HJ (1983) The converting enzyme inhibitor captopril stimulates prostacyclin synthesis by isolated rat aorta. Eur J Pharmacol 91:501–504
Dzau VJ (1988) Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 [Suppl I]:14–113
Faxon DP, Creager MA, Halperin JL, Sussman HA, Gavras H, Ryan TJ (1982) The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease. Int J Cardiol2:252–262
Gilst WH van, Wijngaarden J van, Scholtens E, Graeff PA de, Langen CDJ de, Wesseling H (1987) Captopril-induced increase in coronary flow: an SH-dependent effect on arachidonic acid metabolism? J Cardiovasc Pharmacol 9 [Suppl 2]:S31-S36
Gilst WH van, Scholtens E, Graeff PA de, Langen CDJ de, Wesseling H (1988a) Differential influences of angiotensin converting-enzym inhibitors of the coronary circulation. Circulation 77 [Suppl I]:124–129
Gilst WH van, Ti RA, Wijngaarden J van, Scholtens E, Wesseling H (1988b) The coronary vasodilation mechanism of SH-containing converting enzyme inhibitors: potentiation of endogenous nitrate? Circulation 78 [Suppl 11]:II221
Lee S-L, Levitsky S, Feinberg H (1989) Effects of exogenous vascoconstrictors on coronary vascular resistance and prostacyclin production of the quiescent heart: the inhibitory effect of aspirin. J Pharmacol Exp Ther 248 44–49
Lindpainter K, Jin J, Wilhelm MJ, Suzuki F, Crantz FR, Levine L, Moore TJ, Dluhy RG (1988) Intracardiac generation of angiotensin and its physiological role. Circulation 77 [Suppl I]: I18-I23
Linz W, Schölkens BA, Han YF (1986) Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol 8 [Suppl 10]:S91-S99
Magrini F, Masayoski S, Roberts N, Fouad FM, Tarzi RC, Zanchetti A (1987) Coronary enzyme inhibition and coronary blood flow. Circulation 75:I168-I174
Mattioli G, Zennaro RG, Benassi A, Modena MG, Luppi G (1984) Coronary blood flow modification after administration of captopril. In: Mehl W, Wolmer E (eds) The coronary sinus. Springer, New York Berlin Heidelberg, pp 221–226
Mullane KM Moncada S (1980) PG12 mediates the potentiated hypotensive effect of bradykinin following captopril treatment. Eur J Pharmacol66:355–365
Mullane KM, Moncada S, Vane JR (1982) Does prostaglandin release contribute to the hypotension induced by inhibitors of angiotensin converting enzyme? In: Dunn MJ, Patrono C, Cinotti GA (eds) Prostaglandins and the kidney. Plenum, New York, pp 213–233
Schölkens BA, Linz W, König W (1988) Role of bradykinin in the cardiac action of the converting enzyme inhibitor ramipril. Eur Heart J 9 [Suppl A]:P398
Schrör K, Metz U, Krebs R (1979) The bradykinin-induced coronary vasodilation. Evidence for an additional prostacyclin-independent mechanism. Naunyn-Schmiedeberg's Arch Pharmacol 307:213–221
Swartz SL, Williams GH (1982) Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol49:1405–1409
Swartz SL, Williams GH, HollenbergNK, Suzuki F, Linz W, Schölkens BA, Ganten D (1980) Increase in Prostaglandins during converting enzyme inhibition. Clin Sci 59 (Suppl 6): 133s-135s
Tallarida RJ, Jacob LS (1979) Construction of dose-response curves: statistical considerations. In: Tallarida RJ, Jacob LS (eds) The dose-response relation in pharmacology. Springer, New York Berlin Heidelberg, pp 85–110
Tio RA, Van Wijngaarden J, Scholtens E, Van Gilst WH, De Langen CDJ, Wesseling H (1989) The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent. In: Schrör K, Sinzinger H (eds) Prostaglandins in clinical research: cardiovascular system. Alan R. Liss, New York, pp 435–439
Tio RA, Heiligers JPC, Langen CDJ de, Gilst WH van, König W, Saxena PR, Wesseling H (1989) The hemodynamic effects of two ACE inhibitors, enalaprilate and zofenoprilate, in the rat: evidence for the involvement of bradykinin. J Hypertens (Suppl 6):S296-S297
Zusman RM (1987) Effects of converting-enzyme inhibitors of the renin-angiotensin-aldosterone, bradykinin, and arachidonicprostaglandin system: correlation of chemical structure and biologic activity. Am J Kidney Dis 10 [Suppl 1]:13–23
Author information
Authors and Affiliations
Additional information
Send offprint requests to J. van Wijngaarden at the above address
Rights and permissions
About this article
Cite this article
van Wijngaarden, J., Tio, R.A., van Gilst, W.H. et al. Coronary vasodilation induced by captopril and zofenoprilat: evidence for a prostaglandin-independent mechanism. Naunyn-Schmiedeberg's Arch Pharmacol 343, 491–495 (1991). https://doi.org/10.1007/BF00169551
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00169551